Komodo Health’s Post

Understanding HCRU and cost by care setting is one of HEOR teams’ greatest challenges. The lack of standardization across datasets, redacted payer info in claims, and missing data variables make it nearly impossible. That’s why our research data schema and cost imputation model (built on 4.4 billion healthcare claims) are so valuable. Learn more: https://lnkd.in/dGTUXFs3 #fda #pharmaceuticalindustry #pharmaceuticals #lifesciences

The ability to identify the setting of care (e.g., inpatient, outpatient, ER, ASC) is consistently one of the top considerations when working with HEOR teams on their projects and studies. The US healthcare system is incredibly complex, as is the medical and pharmacy claims data that Life Science teams rely on to understand real-world scenarios. This data is crucial for HEOR teams to develop strategies that improve health equity. Curating robust research datasets is challenging, and I am incredibly proud of where Komodo's Research Dataset (KRD) stands today. We've empowered HEOR/RWE teams to address research questions that were previously unanswerable with real-world datasets. Understanding patient costs by the setting of care is just one of the complex use cases enabled by KRD. Check out my article below to learn more about how we helped Janssen's Prostate Cancer team uncover critical insights: prior to first-line therapy initiation, prostate cancer–related total costs post-progression to mCRPC were twice as high as pre-progression, and four times higher once first-line mCRPC therapy was initiated. #HEOR #realworlddata #healthequity #datascience #prostatecancer #healtheconomics #evidencegeneration #patientcentricity #KomodoHealth

Understanding HCRU and cost by care setting is one of HEOR teams’ greatest challenges. The lack of standardization across datasets, redacted payer info in claims, and missing data variables make it nearly impossible. That’s why our research data schema and cost imputation model (built on 4.4 billion healthcare claims) are so valuable. Learn more: https://lnkd.in/dGTUXFs3 #fda #pharmaceuticalindustry #pharmaceuticals #lifesciences                       

Understanding HCRU and cost by care setting is one of HEOR teams’ greatest challenges. The lack of standardization across datasets, redacted payer info in claims, and missing data variables make it nearly impossible. That’s why our research data schema and cost imputation model (built on 4.4 billion healthcare claims) are so valuable. Learn more: https://lnkd.in/dGTUXFs3 #fda #pharmaceuticalindustry #pharmaceuticals #lifesciences        

Understanding HCRU and cost by care setting is one of HEOR teams’ greatest challenges. The lack of standardization across datasets, redacted payer info in claims, and missing data variables make it nearly impossible. That’s why our research data schema and cost imputation model, built on 4.4 billion healthcare claims, are so valuable. Learn more: https://lnkd.in/dGTUXFs3 #fda #pharmaceuticalindustry #pharmaceuticals #lifesciences

Harnessing data for success......empowering businesses to thrive through collaborative analysis, unwavering support, and sustainable growth strategies STATSXPERTS is unbeatable. Let's elevate your company together. click the link and get started https://statsxperts.com #statsxperts #TestimonialThursday #bussinessgrowth #HealthCare #pharmaceuticals #dataanalytics #professionals #bestdatanalysisforyourindustry #academia #industryleaders #businessowners #TeamWork

When planning a scientific engagement strategy, it can be a challenge to match the right expert to each clinical trial, publication, and speaking engagement. Using a KOL data platform as a single source of truth allows for: ⭐ Objective scores for segmentation and tiering ⭐ Standardized, scalable approach across the organization ⭐ Simplified analysis and competitor comparisons ⭐ Target lists that can be regularly refreshed against agreed criteria Learn more about data-driven strategic planning: https://lnkd.in/ewrMn8Hw #medicalaffairs #medicalscienceliaison #pharmaceuticals

Calling all my #clinical and #commercial leaders!! Will you be at DPHARM next week?? Lets grab some time to chat about your patient goals for the remainder of Q4 and 2025!! #askpatients #clinicaldevelopment #patientinsights #patientengagement #patientsupportprograms #brandplanning #clinicaltrials #commercialization #patientresearch #patientpreference

Today’s global health challenges require #digitalhealth solutions and constant innovative approaches. As new technologies impact every aspect of the #biopharmaceutical value chain, from drug discovery to clinical development, our industry is investing in digital health to enhance the contributions we make to patients and health systems around the world. We believe that digital health should create more effective, efficient, and patient-outcome-focused health systems. Our Global Principles on Digital Health, built with EFPIA - European Federation of Pharmaceutical Industries and Associations & #JPMA, guide our work: https://ifpma.info/3I4sqnS

In the world of medical research, Randomized Clinical Trials (RCTs) are essential for ensuring that treatments are safe, effective, and evidence-based. 🔬 From reducing biases to establishing the gold standard for treatment efficacy, RCTs form the backbone of modern healthcare innovations. Learn about their definition, importance, and the rigorous process that drives better patient outcomes in our latest article: https://lnkd.in/gtmKMdNs 💡 Dive deeper into the role RCTs play in advancing medical science and shaping the future of patient care. #ClinicalTrials #Clinicalresearch #ClinicalStudy #PharmaceuticalIndustry #PharmaTech #Pharma #Pharmaceutical #Healthcare #HealthcareIndustry #HealthcareSector #HealthcareInnovation #Compliance #Blog #Blogs #Octalsoft